TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29296798

Group type: EXPERIMENTAL
Intervention: Panobinostat with lenalidomide and dexamethasone (FRD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Panobinostat with lenalidomide and dexamethasone (FRD) in lenalidomide-refractory patients
Number of subjects: 27
Study: 29296805

Group type: EXPERIMENTAL
Intervention: Idelalisib + Rituximab (IR; 375 mg/m2)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Idelalisib + Bendamustine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Idelalisib + Rituximab + Bendamustine
Number of subjects: 79
Study: 29296838

Group type: EXPERIMENTAL
Intervention: Sonidegib (200 mg/day, 400 mg/day, 600 mg/day) for up to 12 cycles of 28 days each
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 17
Study: 29296867

Group type: EXPERIMENTAL
Intervention: third-party virus-specific T cells (VSTs)
Number of subjects: 30
Study: 29296873

Group type: EXPERIMENTAL
Intervention: Bortezomib maintenance therapy after tandem autologous/allogeneic hematopoietic cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose conditioning regimen with melphalan 200 mg/m2 for autologous hematopoietic cell transplantation
Number of subjects: 0
Study: 29296893

Group type: EXPERIMENTAL
Intervention: Early progression of disease (POD)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Late progression of disease (POD)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: No progression of disease (POD)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Unfavorable-risk cytogenetics (del[11q]/del[17p])
Number of subjects: 829
Study: 29297178

Group type: EXPERIMENTAL
Intervention: 3D movie using oculus glasses and smartphone
Number of subjects: 100
Study: 29297386

Group type: EXPERIMENTAL
Intervention: Informal health providers (traditional birth attendants, traditional healers, village doctors)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Government facility-based care
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Community level interventions and health worker mobilization
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training for informal providers
Number of subjects: 32
Study: 29297412

Group type: EXPERIMENTAL
Intervention: Maternal deaths
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neonatal illness
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perceived postpartum hemorrhage (PPH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neonatal deaths
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Health services
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spiritual care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interventions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perception of outcomes
Number of subjects: 40
Study: 29298115

Group type: EXPERIMENTAL
Intervention: Web-based tracking and feedback (T&F) tool
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 10
Study: 29298525

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Copper intrauterine device (Cu-IUD)
Number of subjects: 512
Study: 29298669

Group type: EXPERIMENTAL
Intervention: Preferred prenatal counselling protocols
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Joint counselling by neonatologist and obstetrician
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Use of supportive materials
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Use of national or local data on outcome statistics
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Shared decision model
Number of subjects: 205
Study: 29298749

Group type: EXPERIMENTAL
Intervention: Active participation in SmartCare service (transmitting data 3+ times/week or health consultations 5+ times in 24 weeks)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Passive participation in SmartCare service (did not meet active criteria)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (did not use SmartCare service)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 405
Study: 29298798

Group type: EXPERIMENTAL
Intervention: M7824 (MSB0011359C)
Number of subjects: 0
Study: 29298867

Group type: EXPERIMENTAL
Intervention: dezamizumab (fully humanized monoclonal IgG1 anti-SAP antibody)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: miridesap (small-molecule drug)
Number of subjects: 23
Study: 29299030

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Discontinuation of warfarin in low-risk patients with sustained sinus rhythm
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: COMPARATOR
Intervention: Reference group (subjects without AF)
Number of subjects: 171
Study: 29299303

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub (ABHR) and training for hand hygiene (HH) practice during the intervention phase.
Number of subjects: 3335

Group type: EXPERIMENTAL
Intervention: Intervention phase with ABHR and training for HH practice.
Number of subjects: 3335
Study: 29299336

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived systolic time ratio (STR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived pre-ejection period (PEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived left ventricle ejection time (LVET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived D wave
Number of subjects: 0
Study: 29299340

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29299402

Group type: EXPERIMENTAL
Intervention: 10-valent PCV (10vPCV)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: 13-valent PCV (13vPCV)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 262

Group type: COMPARATOR
Intervention: No PPV
Number of subjects: 262
Study: 29299952

Group type: EXPERIMENTAL
Intervention: D-dimer concentrations at early follow-up
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Thrombin peak at early follow-up
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Endogenous thrombin potential (ETP) at early follow-up
Number of subjects: 421
Study: 29299962

Group type: EXPERIMENTAL
Intervention: ROTEM®
Number of subjects: 50
Study: 29300435

Group type: EXPERIMENTAL
Intervention: Lower mean MNA scores (Mini Nutritional Assessment)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Coronary heart disease, systolic and diastolic blood pressure in a sitting position, lower mean MNA scores
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH) prevalence
Number of subjects: 244

Group type: COMPARATOR
Intervention: Number of drugs used or causative drug use
Number of subjects: 244
Study: 29300902

Group type: EXPERIMENTAL
Intervention: Muscle AEA concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Muscle 2-AG concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adipose OEA concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Plasma OEA concentration
Number of subjects: 56
Study: 29300960

Group type: EXPERIMENTAL
Intervention: 12-week intensive exercise intervention
Number of subjects: 26
Study: 29300991

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Severe iatrogenic hypoglycemia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Matched inpatient and outpatient controls
Number of subjects: 19
Study: 29301463

Group type: EXPERIMENTAL
Intervention: Hospitalization-associated disability (HAD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Physical restraints
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Indwelling catheters
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preventive pressure ulcer measures
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hospital stay duration
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Indwelling catheter duration
Number of subjects: 80
Study: 29301486

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) using multidimensional prognostic index (MPI)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) using short physical performance battery (SPPB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Silver Code (based on administrative data)
Number of subjects: 71
Study: 29301519

Group type: EXPERIMENTAL
Intervention: Theory-driven knowledge translation program for improved hand hygiene and aseptic techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitated interprofessional dialogue and learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shift from one-way directed compliance to participatory and meaning-making process
Number of subjects: 0
Study: 29301522

Group type: EXPERIMENTAL
Intervention: Usual care plus e-mail alerts to family physicians and nurses regarding low metabolic indexes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care without e-mail alerts.
Number of subjects: 0
Study: 29301545

Group type: EXPERIMENTAL
Intervention: Personalized training with a-tDCS (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Personalized training with sham-tDCS (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-personalized training with a-tDCS (group 3)
Number of subjects: 0
Study: 29301580

Group type: EXPERIMENTAL
Intervention: BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil)
Number of subjects: 31

Group type: COMPARATOR
Intervention: PEGASYS® (pegylated interferon alfa-2a from Roche Pharmaceutical)
Number of subjects: 31
Study: 29301628

Group type: EXPERIMENTAL
Intervention: Platelet-derived MRP-14
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibody-mediated blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating MRP-14
Number of subjects: 0
Study: 29301865

Group type: EXPERIMENTAL
Intervention: Ultra-HPLC-electron capture atmospheric pressure chemical ionization/high-resolution MS
Number of subjects: 0
Study: 29301921

Group type: EXPERIMENTAL
Intervention: Living well with COPD (LWWCOPD) self-management intervention
Number of subjects: 467
Study: 29301924

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29301973

Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) in the hyperacute phase (0 to 4-6 hours after onset)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) in the acute phase (0 to 24-26 hours after onset)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: First systolic BP recorded at median 23 minutes after onset
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Second systolic BP recorded at emergency department arrival at 57 minutes after onset
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Systolic BP 24 hours after arrival
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Unfavorable outcome at 3 months (modified Rankin Scale, 3-6)
Number of subjects: 386
Study: 29302336

Group type: EXPERIMENTAL
Intervention: Acellular bioscaffolds composed of mammalian extracellular matrix (ECM) implanted with aggressive and early physical therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acellular bioscaffolds with physical therapy
Number of subjects: 13
Study: 29303843

Group type: EXPERIMENTAL
Intervention: LTNPs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Progressors
Number of subjects: 88

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 88
Study: 29304371

Group type: EXPERIMENTAL
Intervention: Rare coding variants in ANGPTL6 (specifically the c.1378A>T allele)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rare coding variants in ANGPTL6
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ANGPTL6 variants
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: History of high blood pressure
Number of subjects: 95
Study: 29304421

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 29304833

Group type: EXPERIMENTAL
Intervention: Selinexor (80 mg/day) in combination with high-dose cytarabine and mitoxantrone (HiDAC/Mito)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg)
Number of subjects: 20
Study: 29305069

Group type: EXPERIMENTAL
Intervention: Real-time feedback in the home plus brief coaching of parents or guardians.
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 298
Study: 29305093

Group type: EXPERIMENTAL
Intervention: Intra-operative fluorescence angiography after tibial bypass surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct revascularised angiosomes (DR)
Number of subjects: 40
Study: 29305116

Group type: EXPERIMENTAL
Intervention: Urinary total plasmin(ogen)/creatinine ratio and plasma concentration of aldosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine albumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemoglobin A
Number of subjects: 0
Study: 29305315

Group type: EXPERIMENTAL
Intervention: RELA haploinsufficiency
Number of subjects: 0
Study: 29305501

Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation or intervention, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Lactobacillus intervention), details not specified
Number of subjects: 0
Study: 29305552

Group type: EXPERIMENTAL
Intervention: Venetoclax (initiated at 20 mg daily, ramped up to 400 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 36
Study: 29305734

Group type: EXPERIMENTAL
Intervention: Olipudase alfa
Number of subjects: 5
Study: 29305847

Group type: COMPARATOR
Intervention: Wheelchair users alone
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Wheelchair users blended with caregivers
Number of subjects: 152
Study: 29305947

Group type: EXPERIMENTAL
Intervention: Ad libitum food intake (3-day average)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overeating 100 Kcal/d above the food intake predicted by 24-h EE at baseline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dietary fat intake
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 61
Study: 29306043

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir for 12 weeks
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir for 24 weeks
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir with Ribavirin for 12 weeks
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir with Ribavirin for 24 weeks
Number of subjects: 667
Study: 29306203

Group type: EXPERIMENTAL
Intervention: Pulsed low-dose rate radiotherapy (PLDR) - 10 fractions of 2 Gy/day, with an interval of 3 minutes, for 5 days per week; dose rate 6.67 cGy/min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pulsed low-dose rate radiotherapy (PLDR)
Number of subjects: 22
Study: 29306459

Group type: EXPERIMENTAL
Intervention: Serum uric acid (sUA) levels
Number of subjects: 7531

Group type: EXPERIMENTAL
Intervention: Serum uric acid (sUA) levels (using diuretics)
Number of subjects: 7531

Group type: EXPERIMENTAL
Intervention: Serum uric acid (sUA) levels (not using diuretics)
Number of subjects: 7531
Study: 29306506

Group type: COMPARATOR
Intervention: On-time dosing (control group)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Substantially late dose 3 (group 2)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Substantially late dose 2, on-time dose 3 (group 3)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Both doses substantially late (group 4)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: On-time dose 2
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Substantially late dose 2
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Participants ≥15 years old
Number of subjects: 1321
Study: 29306587

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 11422

Group type: EXPERIMENTAL
Intervention: Death after surgery
Number of subjects: 11422

Group type: EXPERIMENTAL
Intervention: Infection as a complication
Number of subjects: 11422
Study: 29306769

Group type: EXPERIMENTAL
Intervention: Ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 25
Study: 29306872

Group type: EXPERIMENTAL
Intervention: Progressors (66 patients, 22.5%)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Predictive model including mRSS and duration of skin thickening
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Predictive model including mRSS, duration of skin thickening, and Pol3 positivity
Number of subjects: 326
Study: 29306876

Group type: EXPERIMENTAL
Intervention: Perinatal depression diagnosed in the first trimester of pregnancy
Number of subjects: 568
Study: 29307383

Group type: EXPERIMENTAL
Intervention: HIV-positive women who acquired HIV after migration
Number of subjects: 980

Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: HIV-positive women who acquired HIV before migration
Number of subjects: 980
Study: 29307520

Group type: EXPERIMENTAL
Intervention: Skeletal muscle ceramides in T2DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fat oxidation rates in ND
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fat oxidation and 24-h RQ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Muscle ceramides in ND
Number of subjects: 0
Study: 29307536

Group type: EXPERIMENTAL
Intervention: Unprovoked venous thromboembolism
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Proximal deep vein thrombosis
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Recurrent venous thromboembolism
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Case-fatality of recurrence
Number of subjects: 991
Study: 29307722

Group type: COMPARATOR
Intervention: Internet-based exercise training (IBET)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 350
Study: 29308669

Group type: EXPERIMENTAL
Intervention: Immunosuppression regimen (basiliximab, tacrolimus, mycophenolate, and prednisone)
Number of subjects: 31
Study: 29309249

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study: 29309319

Group type: EXPERIMENTAL
Intervention: Low-risk group (50 mg/kg TXA bolus)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-risk group (loading dose 30 mg/kg, infusion 16 mg/kg/h with 2 mg/kg in pump prime)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 29309521

Group type: EXPERIMENTAL
Intervention: Live zoster vaccine
Number of subjects: 1400000
Study: 29309629

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 143
Study: 29310641

Group type: EXPERIMENTAL
Intervention: Initial treatment (specifics not provided)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires (EuroQoL EQ-5D-5 L, EORTC QLQ-C30, QLQ-BR23, Hospital Anxiety and Depression Scale)
Number of subjects: 13
Study: 29310710

Group type: EXPERIMENTAL
Intervention: Active LLLT (low-level laser therapy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham LLLT (placebo group)
Number of subjects: 36
Study: 29310869

Group type: EXPERIMENTAL
Intervention: Intraosseous vascular access
Number of subjects: 13155

Group type: COMPARATOR
Intervention: Intravenous vascular access
Number of subjects: 13155
Study: 29310928

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks
Number of subjects: 103
Study: 29310998

Group type: EXPERIMENTAL
Intervention: Excess visceral adipose tissue (VAT) ≥100 cm²
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Coronary artery calcifications (CAC)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 118
Study: 29311069

Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam, single-dose administration, specific dosage not mentioned.
Number of subjects: 0
Study: 29311086

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine; specific dosage and duration not provided
Number of subjects: 0
Study: 29311094

Group type: EXPERIMENTAL
Intervention: Telavancin at fixed doses
Number of subjects: 0
Study: 29311357

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 242
Study: 29312109

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy after alteplase
Number of subjects: 70

Group type: COMPARATOR
Intervention: Alteplase-only
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 70
Study: 29312116

Group type: EXPERIMENTAL
Intervention: EMG-driven NMES-robotic hand-assisted upper-limb training
Number of subjects: 0
Study: 29312123

Group type: EXPERIMENTAL
Intervention: 3-months supervised endurance/strength training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age/gender-matched individuals)
Number of subjects: 0
Study: 29312761

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: China Alair System Registry Study (NCT02206269)
Number of subjects: 0
Study: 29312786

Group type: EXPERIMENTAL
Intervention: Propofol plus Fentanyl
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam plus Fentanyl
Number of subjects: 100
Study: 29312948

Group type: EXPERIMENTAL
Intervention: Controlled diet of 1.2 g/kg protein for 2 days
Number of subjects: 0
Study: 29313106

Group type: EXPERIMENTAL
Intervention: Alcohol-related cues
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 31
Study: 29313223

Group type: EXPERIMENTAL
Intervention: Population Health Coordinator (PHC) plus Information Technology (IT) system
Number of subjects: 41555

Group type: COMPARATOR
Intervention: Information Technology (IT) system alone
Number of subjects: 41555